Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals funds global research grants and studies to advance science and patient care in cystic fibrosis, pain, IgA nephropathy, and related serious diseases.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (CF, Pain, IgA nephropathy, most grants/sponsorships) | 2026 (Circle of Care, RIA, VIA cycles reopen)
Funding Amounts: No fixed cap for most grants/ISS; RIA: up to $750,000 over 3 years (Independent), $125,000 over 2 years (Mentored); VIA: up to $750,000/project; typical overhead not to exceed 35%.
Summary: Vertex supports independent research, grants, and sponsorships to advance care and innovation in cystic fibrosis and other serious diseases.
Key Information: ISS/grants are open globally (with some US-only topics); beta thalassemia/sickle cell ISS by RFP only.
Description
Vertex Pharmaceuticals funds a broad portfolio of external programs to advance research, education, and patient care in cystic fibrosis (CF), pain, and other serious diseases. Opportunities include Investigator Sponsored Studies (ISS), independent medical education grants, patient and caregiver initiatives, and sponsorships for medical, scientific, and nonprofit community events. Specialized programs such as the Circle of Care, CF Research Innovation Awards (RIA), and Vertex Innovation Awards (VIA) focus on supporting the CF community and fostering new research and innovation. Funding is available globally, with some disease areas or grant types limited to the US or specific RFP cycles.
